TY - JOUR
T1 - Comorbidity between major depressive disorder and physical diseases
T2 - a comprehensive review of epidemiology, mechanisms and management
AU - Berk, Michael
AU - Köhler-Forsberg, Ole
AU - Turner, Megan
AU - Penninx, Brenda W J H
AU - Wrobel, Anna
AU - Firth, Joseph
AU - Loughman, Amy
AU - Reavley, Nicola J
AU - McGrath, John J
AU - Momen, Natalie C
AU - Plana-Ripoll, Oleguer
AU - O'Neil, Adrienne
AU - Siskind, Dan
AU - Williams, Lana J
AU - Carvalho, Andre F
AU - Schmaal, Lianne
AU - Walker, Adam J
AU - Dean, Olivia
AU - Walder, Ken
AU - Berk, Lesley
AU - Dodd, Seetal
AU - Yung, Alison R
AU - Marx, Wolfgang
N1 - © 2023 World Psychiatric Association.
PY - 2023/10/1
Y1 - 2023/10/1
N2 - Populations with common physical diseases - such as cardiovascular diseases, cancer and neurodegenerative disorders - experience substantially higher rates of major depressive disorder (MDD) than the general population. On the other hand, people living with MDD have a greater risk for many physical diseases. This high level of comorbidity is associated with worse outcomes, reduced adherence to treatment, increased mortality, and greater health care utilization and costs. Comorbidity can also result in a range of clinical challenges, such as a more complicated therapeutic alliance, issues pertaining to adaptive health behaviors, drug-drug interactions and adverse events induced by medications used for physical and mental disorders. Potential explanations for the high prevalence of the above comorbidity involve shared genetic and biological pathways. These latter include inflammation, the gut microbiome, mitochondrial function and energy metabolism, hypothalamic-pituitary-adrenal axis dysregulation, and brain structure and function. Furthermore, MDD and physical diseases have in common several antecedents related to social factors (e.g., socioeconomic status), lifestyle variables (e.g., physical activity, diet, sleep), and stressful live events (e.g., childhood trauma). Pharmacotherapies and psychotherapies are effective treatments for comorbid MDD, and the introduction of lifestyle interventions as well as collaborative care models and digital technologies provide promising strategies for improving management. This paper aims to provide a detailed overview of the epidemiology of the comorbidity of MDD and specific physical diseases, including prevalence and bidirectional risk; of shared biological pathways potentially implicated in the pathogenesis of MDD and common physical diseases; of socio-environmental factors that serve as both shared risk and protective factors; and of management of MDD and physical diseases, including prevention and treatment. We conclude with future directions and emerging research related to optimal care of people with comorbid MDD and physical diseases.
AB - Populations with common physical diseases - such as cardiovascular diseases, cancer and neurodegenerative disorders - experience substantially higher rates of major depressive disorder (MDD) than the general population. On the other hand, people living with MDD have a greater risk for many physical diseases. This high level of comorbidity is associated with worse outcomes, reduced adherence to treatment, increased mortality, and greater health care utilization and costs. Comorbidity can also result in a range of clinical challenges, such as a more complicated therapeutic alliance, issues pertaining to adaptive health behaviors, drug-drug interactions and adverse events induced by medications used for physical and mental disorders. Potential explanations for the high prevalence of the above comorbidity involve shared genetic and biological pathways. These latter include inflammation, the gut microbiome, mitochondrial function and energy metabolism, hypothalamic-pituitary-adrenal axis dysregulation, and brain structure and function. Furthermore, MDD and physical diseases have in common several antecedents related to social factors (e.g., socioeconomic status), lifestyle variables (e.g., physical activity, diet, sleep), and stressful live events (e.g., childhood trauma). Pharmacotherapies and psychotherapies are effective treatments for comorbid MDD, and the introduction of lifestyle interventions as well as collaborative care models and digital technologies provide promising strategies for improving management. This paper aims to provide a detailed overview of the epidemiology of the comorbidity of MDD and specific physical diseases, including prevalence and bidirectional risk; of shared biological pathways potentially implicated in the pathogenesis of MDD and common physical diseases; of socio-environmental factors that serve as both shared risk and protective factors; and of management of MDD and physical diseases, including prevention and treatment. We conclude with future directions and emerging research related to optimal care of people with comorbid MDD and physical diseases.
KW - Depression
KW - cancer
KW - cardiovascular diseases
KW - childhood trauma
KW - collaborative care
KW - comorbidity
KW - digital technologies
KW - inflammation
KW - lifestyle factors
KW - physical diseases
UR - http://www.scopus.com/inward/record.url?scp=85171294939&partnerID=8YFLogxK
UR - https://www.mendeley.com/catalogue/0dda1966-c1b6-31e0-a135-3567c3510dd2/
U2 - 10.1002/wps.21110
DO - 10.1002/wps.21110
M3 - Article
C2 - 37713568
SN - 1723-8617
VL - 22
SP - 366
EP - 387
JO - World psychiatry : official journal of the World Psychiatric Association (WPA)
JF - World psychiatry : official journal of the World Psychiatric Association (WPA)
IS - 3
ER -